Topic

Otsuka Pharmaceuticals Development and Commercialization

Articles

MIDD can pave new road for drug development.

Is Model Informed Drug Development Regulatory Pathway an Exception or the Norm?

Dr. Mark Davies is an NHS Consultant and Director of 

. He has a background in marketing and advertising with an MBA and now works extensively with pharma teams supporting market access, brand strategy, commercial performance, partnership projects and real-world data projects (in partnership with Manchester University).

, a consultancy that provides medical affairs advice, resources, and capabilities. Paul has an MBA, a PhD, and is a Chartered Manager. He has 20 years of pharma industry experience, working in medical affairs, clinical development, and commercial roles.

Mark Davies and Paul Riley outline their blueprint for exploring how healthcare companies can leverage real-world evidence to access and engage customers more effectively.





Optimizing the Value of Real-World Evidence Projects

Elaine Quilici is Pharmaceutical Executive's Editor-in-Chief. Email her at equilici@mjhlifesciences.com

With a background in pharma and biotech, ImmunoGen president and CEO Mark Enyedy discusses his dedication to oncology and the lessons he’s learned along the way.

Q&A: Mark Enyedy, ImmunoGen

's Online and European Editor. He can be reached at jupton@mjhlifesciences.com

AstraZeneca’s Mina Makar and Amgen’s Kave Niksefat talk about how the two companies worked together to develop the new asthma treatment, tezepelumab.

Advancing in Asthma

Marcelo Bigal, M.D, Ph.D, President and CEO of Ventus Therapeutics, talks about how technological innovation in the field of small molecule drug development has created new opportunities for pursuing undruggable targets, building on the well-established strengths of small molecule medicines.










Broadening the Scope of Small Molecules: Ventus Therapeutics

With technological advancements in affinity tuning and real-time tracking of CAR-T cells, the hope is that CAR-T therapy can be effectively applied to treating solid tumors, improve patient outcomes, and avoid the toxicities seen with certain treatments in the clinic.

Tuning and Tracking CAR-T Cells for Safer and More Effective Treatment for Solid Tumors 

Julian Upton is Pharmaceutical Executive’s European and Online Editor. He can be reached at 

How Gilead readied remdesivir for the COVID challenge.

Betting on Its Base in Virology

Inside Regeneron’s monoclonal antibody development to treat COVID.

Scientific Rigor, Urgent Action

Past lessons, strong resolve, and complex coordination propel J&J’s vaccine efforts.

Meeting the Crisis Head-On

Thrust into a commercial-stage company in just months, Moderna moves full steam ahead.

R&D/Clinical Trials